Autres langues Ainos, Inc.

Actions

AIMD

US00902F3038

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
1,04 ^USD	+0,01 %		+0,98 %	-49,26 %

11/03	Les traders anticipent le rapport sur l'inflation alors que les actions américaines ouvrent en baisse à Wall Street	MT
11/03	Principales baisses du prémarché	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer	19/03
Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer	15/03
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	11/03
Top Premarket Decliners	11/03
Ainos : Reports Full Year 2023 Financial Results - Form 8-K	08/03
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
Top Premarket Gainers	08/03
Ainos Submits Clinical Hold Complete Response to US FDA to Address Issues in Phase 2 Veldona Trial	05/02
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms	05/02
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th	01/02
Ainos Announces $1.75 Million Follow-On Funding	25/01
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation	12/01
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	05/01
Ainos Regains Compliance With Nasdaq Listing Rule	02/01
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell	26/12
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary	22/12
Ainos, Inc. Announces Stock Consolidation	13/12
Ainos : Private Placement - Form 8-K	24/11
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data	21/11
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA	21/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ainos, Inc.

Actions

AIMD

US00902F3038

Autres langues

Filtres